A Phase 3 interventional study of Alirocumab and Placebo in Hypercholesterolemia, sponsored by Sanofi. Completed at 30 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-01-23.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.
Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 20th largest by enrollment, is one of 3 that started in 2015, is one of 20 in phase 3, and was the 29th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18+
By country, each count listing its studies:
alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 163 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 107 across the 43 interventional studies. Of the 40 that completed or were terminated, 30 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 43 have an industry lead sponsor. The 6 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
38 studies in Hypercholesterolemia by Sanofi: none open now, none under way, none of them phase 3. Of 38 finished, 22 (58%) have results posted.
Among the 38 studies in Hypercholesterolemia by Sanofi, this one is the 20th largest by enrollment, is one of 4 that started in 2015, is one of 22 in phase 3, and was the 29th registered.
Sanofi’s Hypercholesterolemia studies by the year they started, since 2007.
2 of the studies testing alirocumab in Hypercholesterolemia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07477704Regeneron PharmaceuticalsA Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia | 2026-12-29 |
| NCT07581808University Medical Centre LjubljanaDual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 43 studies testing alirocumab in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 38 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by alirocumab administration as add-on therapy to non-statin lipid modifying therapy (LMT) including diet therapy alone or the lowest strength of statin in comparison with placebo after 12 weeks of treatment in participants with hypercholesterolemia.
Secondary Objective:
The duration of study per participant was approximately 71 weeks consisting of a run-in period (4 weeks), a screening period (3 weeks), a double-blind treatment period (12 weeks), and an open-label treatment period (52 weeks).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants with hypercholesterolemia (heFH or non-FH) receiving non statin LMTs or the lowest strength of statin.
Exclusion criteria:
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Double-blind treatment period(DBTP):participants received Alirocumab 150 mg subcutaneous injection every 4 week(Q4W) alternating with placebo(for alirocumab)Q4W added to lowest-strength statin therapy(atorvastatin 5 mg daily),stable non-statin LMT/diet therapy alone for 12weeks. Participants completed DBTP,entered open-label treatment period(OLTP),received alirocumab 150 mg Q4W up to additional 52 weeks. Alirocumab dose up-titrated to 150 mg every 2 weeks(Q2W) at Week 24(OLTP:Week 12),when targeted LDL-C level at Week 20 not achieved as Japan Atherosclerosis Society Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012:1) ≥100 mg/dL(2.59 mmol/L) in heterozygous familial hypercholesterolemia (heFH) participants/non-familial hypercholesterolemia (non-FH)participants with history of documented coronary heart disease;2) ≥120 mg/dL(3.10 mmol/L)in non-FH participants with history of documented diseases/other risk factors as categorized in primary prevention category III)
Drug: Alirocumab · Drug: Placebo · Drug: Atorvastatin · Drug: Non-statin Lipid-Modifying Therapy · Other: Diet Alone
In DBTP, participants received Alirocumab 150 mg subcutaneous (SC) injection Q2W added to lowest-strength statin therapy (atorvastatin 5 mg daily), stable non-statin LMT or diet therapy alone for 12 weeks. Participants who completed DBTP were entered in OLTP and received alirocumab 150 mg Q4W up to additional 52 weeks. Alirocumab dose up-titrated to 150 mg Q2W at Week 24 (Week 12 of OLTP), when targeted LDL-C levels at Week 20 were not achieved i.e. LDL-C ≥100 mg/dL (2.59 mmol/L) or ≥120 mg/dL (3.10 mmol/L) according to Japan Atherosclerosis Society(JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012.
Drug: Alirocumab · Drug: Atorvastatin · Drug: Non-statin Lipid-Modifying Therapy · Other: Diet Alone
In DBTP, participants received Placebo (for alirocumab) SC injection Q2W added to lowest-strength statin therapy (atorvastatin 5 mg), stable non-statin LMT or diet therapy alone for 12 weeks. Participants who completed DBTP were entered in OLTP and received alirocumab 150 mg Q4W up to additional 52 weeks. Alirocumab dose up-titrated to 150 mg Q2W at Week 24 (Week 12 of OLTP), when targeted LDL-C levels at Week 20 were not achieved i.e. LDL-C ≥100 mg/dL (2.59 mmol/L) or ≥120 mg/dL (3.10 mmol/L) according to JAS Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012.
Drug: Placebo · Drug: Atorvastatin · Drug: Non-statin Lipid-Modifying Therapy · Other: Diet Alone
Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.
Also known as: SAR236553, REGN727
Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.
Atorvastatin 5 mg tablet orally.
Ezetimibe, Bezafibrate or Fenofibrate at stable dose as background therapy.
Stable cholesterol-lowering diet as background therapy.
Percent Change From Baseline in Calculated LDL-C at Week 12- Intent to Treat (ITT) Analysis
Adjusted Least-squares (LS) means and standard errors at Week 12 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment were used in the model (ITT analysis).
Time frame: From Baseline to Week 12
Percent Change From Baseline in Calculated LDL-C at Week 12- On-Treatment Analysis
Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 12 (i.e. up to 21 days after last double-blind injection).
Time frame: From Baseline to Week 12
Percent Change From Baseline in Calculated LDL-C to Averaged Week 10 to 12: ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment and assigning a weight of 0.5 for Week 10 and 12 time points.
Time frame: From Baseline to Week 12
Percent Change From Baseline in Calculated LDL-C to Averaged Week 10 to 12- On-Treatment Analysis
Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 12 (i.e. up to 21 days after last double-blind injection) and assigning a weight of 0.5 for Week 10 and 12 time points.
Time frame: From Baseline to Week 12
Percent Change From Baseline in Apolipoprotein B (Apo-B) at Week 12: ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 12
Percent Change From Baseline in Apo-B at Week 12- On-Treatment Analysis
Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including available post-baseline on-treatment data at from Week 4 to Week 12 (i.e. up to 21 days after last double-blind injection).
Time frame: From Baseline to Week 12
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12: ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 12
Percent Change From Baseline in Non-HDL-C at Week 12- On-treatment Analysis
Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 12 (i.e. up to 21 days after last double-blind injection).
Time frame: From Baseline to Week 12
Percent Change From Baseline in Total Cholesterol (Total-C) at Week 12- ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 12
Percentage of Participants Reaching Calculated LDL-C Goal at Week 12- ITT Analysis
Calculated LDL-C goal was defined as calculated LDL-C \<100 mg/dL (2.59 mmol/L) for heterozygous familiar hypercholesterolemia (heFH) participants or non-familial hypercholesterolemia (non-FH) participants who had a history of documented CHD, or \<120 mg/dL (3.10 mmol/L) for non-FH participants who had a history of documented diseases or other risk factors as defined in JAS Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012. Adjusted percentages at Week 12 were obtained from multiple imputation approach for handling of missing data. All available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment were included in the imputation model.
Time frame: Up to Week 12
Percentage of Participants Reaching Calculated LDL-C Goal at Week 12- On-Treatment Analysis
Calculated LDL-C goal was defined as calculated LDL-C \<100 mg/dL (2.59 mmol/L) for heFH participants or non-FH participants who had a history of documented CHD, or \<120 mg/dL (3.10 mmol/L) for non-FH participants who had a history of documented diseases or other risk factors as defined in JAS Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012. Adjusted percentages at Week 12 from multiple imputation approach including available post-baseline on-treatment data from Week 4 to Week 12 (i.e. up to 21 days after last double-blind injection).
Time frame: Up to Week 12
Percent Change From Baseline in Lipoprotein (a) at Week 12: ITT Analysis
Adjusted means and standard errors at Week 12 were obtained from multiple imputation approach followed by robust regression model for handling of missing data. All available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment were included in the imputation model.
Time frame: From Baseline to Week 12
Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 12- ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 12
Percent Change From Baseline in Fasting Triglycerides (TGs) at Week 12: ITT Analysis
Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 12
Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 12: ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 12
Percent Change From Baseline in Calculated LDL-C at Week 20, 24, 36, 48 and 64 -OLTP Analysis
Time frame: Baseline, Weeks 20, 24, 36, 48 and 64
The study was conducted at 30 active centers in Japan. Overall 241 participants were screened between 30 November 2015 and 19 October 2016, of whom 78 were screen failures and 163 were randomized. Screen failures were mainly due to exclusion criteria met.
| Milestone | Alirocumab 150 mg Q4W | Alirocumab 150 mg Q2W | Placebo Q2W |
|---|---|---|---|
| Started | 54 | 53 | 56 |
| Itt population | 54 | 53 | 56 |
| Mitt population | 54 | 53 | 56 |
| Safety population | 54 | 53 | 56 |
| Completed | 54 | 51 | 55 |
| Not completed | 0 | 2 | 1 |
| Withdrew: Participant withdrew consent | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 | 0 |
| Withdrew: Family matter | 0 | 1 | 0 |
| Milestone | Alirocumab 150 mg Q4W | Alirocumab 150 mg Q2W | Placebo Q2W |
|---|---|---|---|
| Started | 54 | 51 | 55 |
| Treated | 54 | 50 | 54 |
| Completed | 52 | 47 | 47 |
| Not completed | 2 | 4 | 8 |
| Withdrew: Participant withdrew consent | 0 | 0 | 4 |
| Withdrew: Adverse event | 2 | 2 | 3 |
| Withdrew: Physician decision | 0 | 1 | 0 |
| Withdrew: Entered but not treated | 0 | 1 | 1 |
Adjusted Least-squares (LS) means and standard errors at Week 12 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment were used in the model (ITT analysis).
| percent change | Alirocumab 150 mg Q4W | Alirocumab 150 mg Q2W | Placebo Q2W |
|---|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 12- Intent to Treat (ITT) Analysis | -43.8 ± 2.2 | -70.1 ± 2.3 | -4.3 ± 2.2 |
Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 12 (i.e. up to 21 days after last double-blind injection).
| percent change | Alirocumab 150 mg Q4W | Alirocumab 150 mg Q2W | Placebo Q2W |
|---|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 12- On-Treatment Analysis | -43.4 ± 2.1 | -70.1 ± 2.2 | -2.8 ± 2.1 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment and assigning a weight of 0.5 for Week 10 and 12 time points.
| percent change | Alirocumab 150 mg Q4W | Alirocumab 150 mg Q2W | Placebo Q2W |
|---|---|---|---|
| Percent Change From Baseline in Calculated LDL-C to Averaged Week 10 to 12: ITT Analysis | -54.2 ± 1.9 | -69.9 ± 1.9 | -3.7 ± 1.9 |
Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 12 (i.e. up to 21 days after last double-blind injection) and assigning a weight of 0.5 for Week 10 and 12 time points.
| percent change | Alirocumab 150 mg Q4W | Alirocumab 150 mg Q2W | Placebo Q2W |
|---|---|---|---|
| Percent Change From Baseline in Calculated LDL-C to Averaged Week 10 to 12- On-Treatment Analysis | -54.0 ± 1.9 | -69.9 ± 1.9 | -2.6 ± 1.9 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment.
| percent change | Alirocumab 150 mg Q4W | Alirocumab 150 mg Q2W | Placebo Q2W |
|---|---|---|---|
| Percent Change From Baseline in Apolipoprotein B (Apo-B) at Week 12: ITT Analysis | -32.2 ± 2.0 | -57.9 ± 2.0 | -6.0 ± 2.0 |
Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including available post-baseline on-treatment data at from Week 4 to Week 12 (i.e. up to 21 days after last double-blind injection).
| percent change | Alirocumab 150 mg Q4W | Alirocumab 150 mg Q2W | Placebo Q2W |
|---|---|---|---|
| Percent Change From Baseline in Apo-B at Week 12- On-Treatment Analysis | -31.8 ± 2.0 | -58.0 ± 2.0 | -4.6 ± 1.9 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment.
| percent change | Alirocumab 150 mg Q4W | Alirocumab 150 mg Q2W | Placebo Q2W |
|---|---|---|---|
| Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12: ITT Analysis | -36.2 ± 2.0 | -61.1 ± 2.0 | -4.9 ± 2.0 |
Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 12 (i.e. up to 21 days after last double-blind injection).
| percent change | Alirocumab 150 mg Q4W | Alirocumab 150 mg Q2W | Placebo Q2W |
|---|---|---|---|
| Percent Change From Baseline in Non-HDL-C at Week 12- On-treatment Analysis | -35.9 ± 1.9 | -61.1 ± 2.0 | -3.5 ± 1.9 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment.
| percent change | Alirocumab 150 mg Q4W | Alirocumab 150 mg Q2W | Placebo Q2W |
|---|---|---|---|
| Percent Change From Baseline in Total Cholesterol (Total-C) at Week 12- ITT Analysis | -25.8 ± 1.5 | -44.7 ± 1.6 | -3.3 ± 1.5 |
Calculated LDL-C goal was defined as calculated LDL-C \<100 mg/dL (2.59 mmol/L) for heterozygous familiar hypercholesterolemia (heFH) participants or non-familial hypercholesterolemia (non-FH) participants who had a history of documented CHD, or \<120 mg/dL (3.10 mmol/L) for non-FH participants who had a history of documented diseases or other risk factors as defined in JAS Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012. Adjusted percentages at Week 12 were obtained from multiple imputation approach for handling of missing data. All available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment were included in the imputation model.
| percentage of participants | Alirocumab 150 mg Q4W | Alirocumab 150 mg Q2W | Placebo Q2W |
|---|---|---|---|
| Percentage of Participants Reaching Calculated LDL-C Goal at Week 12- ITT Analysis | 85.2 | 96.2 | 14.3 |
Calculated LDL-C goal was defined as calculated LDL-C \<100 mg/dL (2.59 mmol/L) for heFH participants or non-FH participants who had a history of documented CHD, or \<120 mg/dL (3.10 mmol/L) for non-FH participants who had a history of documented diseases or other risk factors as defined in JAS Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012. Adjusted percentages at Week 12 from multiple imputation approach including available post-baseline on-treatment data from Week 4 to Week 12 (i.e. up to 21 days after last double-blind injection).
| percentage of participants | Alirocumab 150 mg Q4W | Alirocumab 150 mg Q2W | Placebo Q2W |
|---|---|---|---|
| Percentage of Participants Reaching Calculated LDL-C Goal at Week 12- On-Treatment Analysis | 85.2 | 96.2 | 10.8 |
Adjusted means and standard errors at Week 12 were obtained from multiple imputation approach followed by robust regression model for handling of missing data. All available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment were included in the imputation model.
| percent change | Alirocumab 150 mg Q4W | Alirocumab 150 mg Q2W | Placebo Q2W |
|---|---|---|---|
| Percent Change From Baseline in Lipoprotein (a) at Week 12: ITT Analysis | -31.7 ± 3.3 | -49.6 ± 3.3 | 1.3 ± 3.3 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment.
| percent change | Alirocumab 150 mg Q4W | Alirocumab 150 mg Q2W | Placebo Q2W |
|---|---|---|---|
| Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 12- ITT Analysis | 7.7 ± 1.8 | 9.9 ± 1.8 | 2.0 ± 1.8 |
Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment.
| percent change | Alirocumab 150 mg Q4W | Alirocumab 150 mg Q2W | Placebo Q2W |
|---|---|---|---|
| Percent Change From Baseline in Fasting Triglycerides (TGs) at Week 12: ITT Analysis | -0.6 ± 3.7 | -18.0 ± 3.8 | -6.4 ± 3.7 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment.
| percent change | Alirocumab 150 mg Q4W | Alirocumab 150 mg Q2W | Placebo Q2W |
|---|---|---|---|
| Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 12: ITT Analysis | 6.8 ± 1.6 | 9.1 ± 1.7 | 2.9 ± 1.6 |
| Percent change | Alirocumab 150mgQ4W/Up Q2W(After Alirocumab 150mgQ4W in DBTP) | Alirocumab 150mgQ4W/Up Q2W(After Alirocumab 150mgQ2W in DBTP) | Alirocumab 150mg Q4W/Up Q2W (After Placebo Q2W in DBTP) |
|---|---|---|---|
| Week 20 | -42.1 ± 20.1 | -47.8 ± 24.2 | -45.5 ± 20.5 |
| Week 24 | -39.7 ± 20.4 | -46.0 ± 20.0 | -47.8 ± 21.7 |
| Week 36 | -49.2 ± 19.4 | -51.5 ± 19.6 | -56.2 ± 18.8 |
| Week 48 | -48.6 ± 21.6 | -53.9 ± 17.6 | -57.8 ± 17.4 |
| Week 64 | -44.3 ± 22.8 | -55.2 ± 17.5 | -58.1 ± 19.6 |
Collected over All Adverse Events (AEs) were collected from signature of the informed consent form up to the end of study (up to Week 64) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double-blind Treatment Period: Placebo Q2W | 0/56 (0%) | 1/56 (1.8%) | 14/56 (25%) |
| Double-blind Treatment Period: Alirocumab 150 mg Q4W | 0/54 (0%) | 1/54 (1.9%) | 11/54 (20.4%) |
| Double-blind Treatment Period: Alirocumab 150 mg Q2W | 1/53 (1.9%) | 2/53 (3.8%) | 13/53 (24.5%) |
| Open-label Treatment Period: Alirocumab 150 mg Q4W/Up Q2W | 0/158 (0%) | 12/158 (7.6%) | 72/158 (45.6%) |
| Event | Double-blind Treatment Period: Placebo Q2W | Double-blind Treatment Period: Alirocumab 150 mg Q4W | Double-blind Treatment Period: Alirocumab 150 mg Q2W | Open-label Treatment Period: Alirocumab 150 mg Q4W/Up Q2W |
|---|---|---|---|---|
| Metastases to stomachNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/56 | 0/54 | 1/53 | 0/158 |
| Non-small cell lung cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/56 | 0/54 | 1/53 | 0/158 |
| AnaemiaBlood and lymphatic system disorders | 0/56 | 0/54 | 1/53 | 0/158 |
| Dizziness posturalNervous system disorders | 0/56 | 0/54 | 1/53 | 0/158 |
| Loss of consciousnessNervous system disorders | 0/56 | 0/54 | 1/53 | 0/158 |
| Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders | 0/56 | 1/54 | 0/53 | 0/158 |
| Angina unstableCardiac disorders | 1/56 | 0/54 | 0/53 | 0/158 |
| Coronary artery stenosisCardiac disorders | 0/56 | 0/54 | 0/53 | 2/158 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/56 | 0/54 | 0/53 | 1/158 |
| Pituitary tumour benignNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/56 | 0/54 | 0/53 | 1/158 |
| Event | Double-blind Treatment Period: Placebo Q2W | Double-blind Treatment Period: Alirocumab 150 mg Q4W | Double-blind Treatment Period: Alirocumab 150 mg Q2W | Open-label Treatment Period: Alirocumab 150 mg Q4W/Up Q2W |
|---|---|---|---|---|
| Viral upper respiratory tract infectionInfections and infestations | 9/56 | 8/54 | 8/53 | 54/158 |
| Non-cardiac chest painGeneral disorders | 1/56 | 0/54 | 4/53 | 3/158 |
| FallInjury, poisoning and procedural complications | 3/56 | 0/54 | 1/53 | 11/158 |
| PharyngitisInfections and infestations | 0/56 | 3/54 | 0/53 | 5/158 |
| DizzinessNervous system disorders | 3/56 | 0/54 | 0/53 | 2/158 |
| Back painMusculoskeletal and connective tissue disorders | 0/56 | 0/54 | 1/53 | 8/158 |
Baseline population included all randomized participants.
| Age, Continuous(years) | Alirocumab 150 mg Q4W | Alirocumab 150 mg Q2W | Placebo Q2W | Total |
|---|---|---|---|---|
| Mean | 62.6 ± 9.8 | 63.6 ± 10.4 | 64.6 ± 10.0 | 63.6 ± 10.1 |
| Sex: Female, Male(Participants) | Alirocumab 150 mg Q4W | Alirocumab 150 mg Q2W | Placebo Q2W | Total |
|---|---|---|---|---|
| Female | 21 | 20 | 19 | 60 |
| Male | 33 | 33 | 37 | 103 |
| Race/Ethnicity, Customized(Participants) | Alirocumab 150 mg Q4W | Alirocumab 150 mg Q2W | Placebo Q2W | Total |
|---|---|---|---|---|
| Asian | 54 | 53 | 56 | 163 |
| Calculated LDL-C in mg/dL(mg/dL) | Alirocumab 150 mg Q4W | Alirocumab 150 mg Q2W | Placebo Q2W | Total |
|---|---|---|---|---|
| Mean | 154.2 ± 59.5 | 149.2 ± 31.1 | 149.4 ± 32.6 | 150.9 ± 42.8 |
| Calculated LDL-C in mmol/L(mmol/L) | Alirocumab 150 mg Q4W | Alirocumab 150 mg Q2W | Placebo Q2W | Total |
|---|---|---|---|---|
| Mean | 3.993 ± 1.541 | 3.865 ± 0.806 | 3.870 ± 0.844 | 3.909 ± 1.109 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2015 to primary completion in Apr 2017, 16 months.
Results were first posted in May 2018, 1 year 1 month after primary completion.
Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 16 months is below that.
Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alirocumab